Novel therapeutics for gastro-esophageal reflux symptoms

Expert Review of Clinical Pharmacology

Volumn 5, Issue 5, 2012, Pages 533-541

  Zerbib, Frank ^a,b   Simon, Mireille ^a,b  

^a HÔPITAL SAINT ANDRÉ   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

baclofen; esophageal hypersensitivity; GABA receptor; gastro esophageal reflux; glutamate receptor; pain modulators; proton pump inhibitor; transient lower esophageal sphincter relaxation

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; ADX 10059; ARBACLOFEN PLACARBIL; BACLOFEN; LESOGABERAN; LINAPRAZAN; METABOTROPIC RECEPTOR 5; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

CENTRAL NERVOUS SYSTEM; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPIC SURGERY; ESOPHAGUS; ESOPHAGUS MUCOSA; GASTROESOPHAGEAL REFLUX; HUMAN; NAUSEA; REVIEW; SIDE EFFECT; SURGICAL TECHNIQUE; VOMITING;

DRUG DISCOVERY; ESOPHAGEAL SPHINCTER, LOWER; GABA-B RECEPTOR AGONISTS; GASTROESOPHAGEAL REFLUX; HUMANS; PROTON PUMP INHIBITORS; RECEPTORS, METABOTROPIC GLUTAMATE; TREATMENT OUTCOME;

EID: 84868575983     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.12.38     Document Type: Review

References (71)

1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am. J. Gastroenterol. 101(8), 1900-20; quiz 1943 (2006).
2. Vaezi MF, Singh S, Richter JE. Role of acid and duodenogastric reflux in esophageal mucosal injury: a review of animal and human studies. Gastroenterology 108(6), 1897-1907 (1995).
3. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 112(6), 1798-1810 (1997).
4. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 58(2), 295-309 (2009). refractoriness in gastro-esophageal reflux disease (GERD).
5. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment. Pharmacol. Ther. 11(4), 765-773 (1997).
6. Tack J, Fass R. Review article: approaches to endoscopic-negative reflux disease: part of the GERD spectrum or a unique acid-related disorder? Aliment. Pharmacol. Ther. 19(Suppl. 1), 28-34 (2004).
7. Lundell L. Surgical therapy of gastro-oesophageal reflux disease. Best Pract. Res. Clin. Gastroenterol. 24(6), 947-959 (2010).
8. Mainie I, Tutuian R, Shay S et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 55(10), 1398-1402 (2006).
9. Zerbib F, Roman S, Ropert A et al. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am. J. Gastroenterol. 101(9), 1956-1963 (2006).
10. Dent J, Holloway RH, Toouli J, Dodds WJ. Mechanisms of lower oesophageal sphincter incompetence in patients with symptomatic gastrooesophageal reflux. Gut 29(8), 1020-1028 (1988).
11. Sifrim D, Holloway R, Silny J, Tack J, Lerut A, Janssens J. Composition of the postprandial refluxate in patients with gastroesophageal reflux disease. Am. J. Gastroenterol. 96(3), 647-655 (2001).
12. Mittal RK, Holloway RH, Penagini R, Blackshaw LA, Dent J. Transient lower esophageal sphincter relaxation. Gastroenterology 109(2), 601-610 (1995).
13. Bredenoord AJ, Draaisma WA, Weusten BL, Gooszen HG, Smout AJ. Mechanisms of acid, weakly acidic and gas reflux after anti-reflux surgery. Gut 57(2), 161-166 (2008).
14. Lidums I, Lehmann A, Checklin H, Dent J, Holloway RH. Control of transient lower esophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in normal subjects. Gastroenterology 118(1), 7-13 (2000).
15. Zhang Q, Lehmann A, Rigda R, Dent J, Holloway RH. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut 50(1), 19-24 (2002).
16. Vela MF, Tutuian R, Katz PO, Castell DO. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment. Pharmacol. Ther. 17(2), 243-251 (2003).
17. Ciccaglione AF, Marzio L. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut 52(4), 464-470 (2003).
18. Cossentino MJ, Mann K, Armbruster SP, Lake JM, Maydonovitch C, Wong RK. Randomised clinical trial: the effect of baclofen in patients with gastro-oesophageal reflux - a randomised prospective study. Aliment. Pharmacol. Ther. doi:10.1111/j.1365-2036.2012.05068.x (2012) (Epub ahead of print).
19. Koek GH, Sifrim D, Lerut T, Janssens J, Tack J. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 52(10), 1397-1402 (2003).
20. Gerson LB, Huff FJ, Hila A et al. Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. Am. J. Gastroenterol. 105(6), 1266-1275 (2010).
21. Vakil NB, Huff FJ, Bian A, Jones DS, Stamler D. Arbaclofen placarbil in GERD: a randomized, double-blind, placebocontrolled study. Am. J. Gastroenterol. 106(8), 1427-1438 (2011).
22. Boeckxstaens GE, Rydholm H, Lei A, Adler J, Ruth M. Effect of lesogaberan, a novel GABA(B)-receptor agonist, on transient lower oesophageal sphincter relaxations in male subjects. Aliment. Pharmacol. Ther. 31(11), 1208-1217 (2010).
23. Boeckxstaens GE, Beaumont H, Mertens V et al. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology 139(2), 409-417 (2010).
24. Boeckxstaens GE, Beaumont H, Hatlebakk JG et al. A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial. Gut 60(9), 1182-1188 (2011).
25. Hornby PJ. Receptors and transmission in the brain-gut axis. II. Excitatory amino acid receptors in the brain-gut axis. Am. J. Physiol. Gastrointest. Liver Physiol. 280(6), G1055-G1060 (2001).
26. Page AJ, Young RL, Martin CM et al. Metabotropic glutamate receptors inhibit mechanosensitivity in vagal sensory neurons. Gastroenterology 128(2), 402-410 (2005).
27. Jensen J, Lehmann A, Uvebrant A et al. Transient lower esophageal sphincter relaxations in dogs are inhibited by a metabotropic glutamate receptor 5 antagonist. Eur. J. Pharmacol. 519(1-2), 154-157 (2005).
28. Frisby CL, Mattsson JP, Jensen JM, Lehmann A, Dent J, Blackshaw LA. Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands. Gastroenterology 129(3), 995-1004 (2005).
29. Keywood C, Wakefield M, Tack J. A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut 58(9), 1192-1199 (2009).
30. Zerbib F, Keywood C, Strabach G. Efficacy, tolerability and pharmacokinetics of a modified release formulation of ADX10059, a negative allosteric modulator of metabotropic glutamate receptor 5: an esophageal pH-impedance study in healthy subjects. Neurogastroenterol. Motil. 22(8), 859-65, e231 (2010).
31. Zerbib F, Bruley des Varannes S, Roman S et al. Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor, on symptoms and reflux events in patients with gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 33(8), 911-921 (2011).
32. Castell DO, Zerbib F, Bruley Des Varannes S et al. Efficacy and tolerability of ADX10059, a mGluR5 negative allosteric modulator, as add on therapy to proton pump inhibitors (PPIs) in patients with gastroesophageal reflux disease (GERD). Gastroenterology 140, S577 (2011).
33. Rohof WO, Lei A, Hirsch DP et al. The effects of a novel metabotropic glutamate receptor 5 antagonist (AZD2066) on transient lower oesophageal sphincter relaxations and reflux episodes in healthy volunteers. Aliment. Pharmacol. Ther. 35(10), 1231-1242 (2012).
34. Hirsch DP, Holloway RH, Tytgat GN, Boeckxstaens GE. Involvement of nitric oxide in human transient lower esophageal sphincter relaxations and esophageal primary peristalsis. Gastroenterology 115(6), 1374-1380 (1998).
35. Hirsch DP, Tiel-Van Buul MM, Tytgat GN, Boeckxstaens GE. Effect of l-NMMA on postprandial transient lower esophageal sphincter relaxations in healthy volunteers. Dig. Dis. Sci. 45(10), 2069-2075 (2000).
36. Boeckxstaens GE, Hirsch DP, Fakhry N, Holloway RH, D'Amato M, Tytgat GN. Involvement of cholecystokininA receptors in transient lower esophageal sphincter relaxations triggered by gastric distension. Am. J. Gastroenterol. 93(10), 1823-1828 (1998).
37. Zerbib F, Bruley Des Varannes S, Scarpignato C et al. Endogenous cholecystokinin in postprandial lower esophageal sphincter function and fundic tone in humans. Am. J. Physiol. 275(6 Pt 1), G1266-G1273 (1998).
38. Trudgill NJ, Hussain FN, Moustafa M, Ajjan R, D'Amato M, Riley SA. The effect of cholecystokinin antagonism on postprandial lower oesophageal sphincter function in asymptomatic volunteers and patients with reflux disease. Aliment. Pharmacol. Ther. 15(9), 1357-1364 (2001).
39. Penagini R, Bianchi PA. Effect of morphine on gastroesophageal reflux and transient lower esophageal sphincter relaxation. Gastroenterology 113(2), 409-414 (1997).
40. Beaumont H, Jensen J, Carlsson A, Ruth M, Lehmann A, Boeckxstaens G. Effect of Δ9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. Br. J. Pharmacol. 156(1), 153-162 (2009).
41. Jafri SM, Arora G, Triadafilopoulos G. What is left of the endoscopic antireflux devices? Curr. Opin. Gastroenterol. 25(4), 352-357 (2009).
42. Tam WC, Schoeman MN, Zhang Q et al. Delivery of radiofrequency energy to the lower oesophageal sphincter and gastric cardia inhibits transient lower oesophageal sphincter relaxations and gastro-oesophageal reflux in patients with reflux disease. Gut 52(4), 479-485 (2003).
43. Corley DA, Katz P, Wo JM et al. Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled trial. Gastroenterology 125(3), 668-676 (2003).
44. Coron E, Sebille V, Cadiot G et al.; Consortium de Recherche Indépendant sur le Traitement et L'exploration du Reflux Gastro-oesophagien et de L'endobrachyoesophage (CRITERE). Clinical trial: radiofrequency energy delivery in proton pump inhibitordependent gastro-oesophageal reflux disease patients. Aliment. Pharmacol. Ther. 28(9), 1147-1158 (2008).
45. Arts J, Sifrim D, Rutgeerts P, Lerut A, Janssens J, Tack J. Influence of radiofrequency energy delivery at the gastroesophageal junction (the Stretta procedure) on symptoms, acid exposure, and esophageal sensitivity to acid perfusion in gastroesophagal reflux disease. Dig. Dis. Sci. 52(9), 2170-2177 (2007).
46. Frazzoni M, Conigliaro R, Manta R, Melotti G. Reflux parameters as modified by EsophyX or laparoscopic fundoplication in refractory GERD. Aliment. Pharmacol. Ther. 34(1), 67-75 (2011).
47. Barnes WE, Hoddinott KM, Mundy S, Williams M. Transoral incisionless fundoplication offers high patient satisfaction and relief of therapy-resistant typical and atypical symptoms of GERD in community practice. Surg. Innov. 18(2), 119-129 (2011).
48. Bredenoord AJ, Weusten BL, Curvers WL, Timmer R, Smout AJ. Determinants of perception of heartburn and regurgitation. Gut 55(3), 313-318 (2006).
49. Zerbib F, Duriez A, Roman S, Capdepont M, Mion F. Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors. Gut 57(2), 156-160 (2008).
50. Tutuian R, Vela MF, Hill EG, Mainie I, Agrawal A, Castell DO. Characteristics of symptomatic reflux episodes on Acid suppressive therapy. Am. J. Gastroenterol. 103(5), 1090-1096 (2008).
51. Sharma P, Shaheen NJ, Perez MC et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation-results from two randomized controlled studies. Aliment. Pharmacol. Ther. 29(7), 731-741 (2009).
52. Dent J, Kahrilas PJ, Hatlebakk J et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am. J. Gastroenterol. 103(1), 20-26 (2008).
53. Kahrilas PJ, Dent J, Lauritsen K et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin. Gastroenterol. Hepatol. 5(12), 1385-1391 (2007).
54. Galmiche JP, Clouse RE, Bálint A et al. Functional esophageal disorders. Gastroenterology 130(5), 1459-1465 (2006).
55. Knowles CH, Aziz Q. Visceral hypersensitivity in non-erosive reflux disease. Gut 57(5), 674-683 (2008).
56. Reddy H, Staahl C, Arendt-Nielsen L, Gregersen H, Drewes AM, Funch-Jensen P. Sensory and biomechanical properties of the esophagus in non-erosive reflux disease. Scand. J. Gastroenterol. 42(4), 432-440 (2007).
57. Viazis N, Keyoglou A, Kanellopoulos AK et al. Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebocontrolled study. Am. J. Gastroenterol. doi:10.1038/ajg.2011.179 (2011) (Epub ahead of print).
58. Miner PB Jr, Rodriguez-Stanley S, Proskin HM, Kianifard F, Bottoli I. Tegaserod in patients with mechanical sensitivity and overlapping symptoms of functional heartburn and functional dyspepsia. Curr. Med. Res. Opin. 24(8), 2159-2172 (2008).
59. Krarup AL, Ny L, Astrand M et al. Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain. Aliment. Pharmacol. Ther. 33(10), 1113-1122 (2011).
60. Caviglia R, Ribolsi M, Maggiano N et al. Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure. Am. J. Gastroenterol. 100(3), 543-548 (2005).
61. Barlow WJ, Orlando RC. The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology 128(3), 771-778 (2005).
62. van Malenstein H, Farré R, Sifrim D. Esophageal dilated intercellular spaces (DIS) and nonerosive reflux disease. Am. J. Gastroenterol. 103(4), 1021-1028 (2008).
63. Calabrese C, Bortolotti M, Fabbri A et al. Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment. Am. J. Gastroenterol. 100(3), 537-542 (2005).
64. Vela MF, Craft BM, Sharma N, Freeman J, Hazen-Martin D. Refractory heartburn: comparison of intercellular space diameter in documented GERD vs. functional heartburn. Am. J. Gastroenterol. 106(5), 844-850 (2011).
65. Matysiak-Budnik T, Heyman M, Mégraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment. Pharmacol. Ther. 18(Suppl. 1), 55-62 (2003).
66. Yoshida N, Kamada K, Tomatsuri N et al. Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg. lansoprazole. Dig. Dis. Sci. 55(12), 3393-3398 (2010).
67. Abdulnour-Nakhoul S, Tobey NA, Nakhoul NL, Wheeler SA, Vanegas X, Orlando RC. The effect of tegaserod on esophageal submucosal glands bicarbonate and mucin secretion. Dig. Dis. Sci. 53(9), 2366-2372 (2008).
68. Majewski M, Jaworski T, Sarosiek I et al. Significant enhancement of esophageal pre-epithelial defense by tegaserod: implications for an esophagoprotective effect. Clin. Gastroenterol. Hepatol. 5(4), 430-438 (2007).
69. Zerbib F, Belhocine K, Simon M et al. Clinical, but not oesophageal pHimpedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease. Gut 61(4), 501-506 (2012).
70. Nojkov B, Rubenstein JH, Adlis SA et al. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 27(6), 473-482 (2008).
71. Savarino E, Pohl D, Zentilin P et al. Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut 58(9), 1185-1191 (2009).